Related by context. Frequent words. (Click for all words.) 63 RXi Pharmaceutical Corporation 59 * Potentially libelous 58 PLAN OR EXPECT 57 PINNACLEDIGEST.COM S PAST PERFORMANCE 57 concerning Alnylam 57 OR SIMILAR STATEMENTS ARE 57 involves Activision Publishing 57 goals expectations anticipations 56 AS ESTIMATE ANTICIPATE BELIEVE 56 Ligand proprietary 56 PUBLIC WEBSITE WWW.FITCHRATINGS.COM 56 unique PER.C6 ® 56 Adopts Shareholder Rights 56 cancer newsBritish reality 55 WHICH ARE NOT PURELY 55 Application BLA 55 Staff Writer jschramm@minotdailynews.com 55 CONTAINS FORWARD LOOKING STATEMENTS 54 INVESTORS ARE URGED TO 54 By Julian Pecquet 54 topical anti infective 54 WITHOUT ANY WARRANTIES 54 Personalized Sweat Suits Baby 54 HISTORICAL ARE FORWARD LOOKING 54 READ THE PROXY 54 IS NOT INDICATIVE OF 54 submitted Biologics License 54 VERIFICATION OF THE 54 ARE REASONABLE THERE CAN 54 strategy summarization 54 THAT INCLUDE SUCH WORDS 54 SUCH RATINGS ARE AVAILABLE 54 SMARTREND WATCHING FOR 54 STOCKHOLDERS ARE URGED TO 53 THAT ARE PRECEDED BY 53 ATK undertakes 53 BELIEFS PLANS EXPECTATIONS AND 53 WITH THE BENEFIT 53 SHALL NOT CONSTITUTE AN 53 THE MATERIAL IN 53 THAT THEY ARE DESIGNED 53 HAS BEEN PREPARED BY 53 strategy Analyst summarization 53 BEFORE MAKING ANY VOTING 53 using BioSante patented 53 negatives thereof 53 REGULATORY AUTHORITY HAS APPROVED 53 SIMULATED TRADING PROGRAMS IN 53 IN ADDITION RATING DEFINITIONS 53 STATEMENTS OR 53 OF HINDSIGHT 53 SECTION #A OF 53 WITHIN THE MEANING OF 53 TOCOSOL Paclitaxel 53 AS LACK OF LIQUIDITY 53 OF THE ORIGINAL 52 irresponsible nuisances 52 JOINT PROXY STATEMENT PROSPECTUS 52 Staff Writer larry@gaffneyledger.com 52 STATEMENTS AND 52 Threats hate speech 52 FOLLOWED BY OR 52 RELATIVELY GOOD PERFORMANCE DETECTED 52 THERE CAN BE 52 By RYAN BOLAND 52 RR Donnelley disclaims 52 IS FOR INFORMATIONAL 52 IS DEFINED IN 52 Disclaimer Past performance 52 HYPOTHETICAL OR SIMULATED PERFORMANCE 52 Offering Pilates 52 By TheStreet Wire 52 strategy GlobalData summarization 52 NO STOCK EXCHANGE 52 ACS disclaims 52 Regulatory Disclosure 52 By Thomas Gryta 52 OF USE OF 52 % #F# #v.jsn 52 By Katy Burne 52 AFFILIATES AGENTS AND LICENSORS 52 INCLUDE ANY STATEMENTS REGARDING 52 www.twitter.com otcadvisors 52 IS OBTAINED AND 52 By EILEEN SMITH 52 GENERAL ARE ALSO SUBJECT 52 OF THE ABOVE 52 IMPACT IF ANY OF 51 ENTIRETY WHEN THEY BECOME 51 refractory chronic lymphocytic 51 SAFE HARBOR PROVISIONS OF 51 WEBSITE OR THE 51 INTERPRETING REPORTING OR DELIVERING 51 By TERRANCE HARRIS 51 MATERIALLY FROM ANY FUTURE 51 involving hydrophilic liquid 51 Ariba logo AribaLIVE 51 IT WILL CONTAIN 51 CERTAIN MARKET FACTORS SUCH 51 YOU ARE ENTITLED TO 51 objectives expectations anticipations